Clinical Trial Update: Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy [Phase 2]

View source ↗

Summary

Phase II randomized trial updating time to progression for fulvestrant with erlotinib or placebo in hormone receptor–positive metastatic breast cancer that prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: University of Arkansas | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-02-06